Article

Safety, Immunogenicity and Efficacy of the mRNA Vaccine CS-2034 as a Heterologous Booster Versus Homologous Booster with BBIBP-CorV in Adults Aged ≥18 Years: A Randomized, Partial-Blind, Phase 2b Trial

2023-02-15

Abstract excerpt

Background: Heterologous boosting is suggested to use in populations who have received inactivated COVID-19 vaccines. We assessed the safety, immunogenicity of a heterologous vaccination with mRNA vaccine CS-2034 versus BBIBP-CorV as a fourth dose, as well as the efficacy against the SARS-CoV-2 Omicron variant.<br><br>Methods: We did a randomized, partial-blind, parallel-controlled study (ChiCTR2200064575) in heal...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5a1d6bbe-6473-56f3-839e-a74dcdb1eabf
DOI: 10.2139/ssrn.4356787

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Safety, Immunogenicity and Efficacy of the mRNA Vaccine CS-2034 as a Heterologous Booster Versus Homologous Booster with BBIBP-CorV in Adults Aged ≥18 Years: A Randomized, Partial-Blind, Phase 2b TrialDOI 10.2139/ssrn.4356787Read

Antibody Response of Heterologous vs Homologous mRNA Vaccine Boosters Against the SARS-CoV-2 Omicron Variant: Interim Results from the PRIBIVAC Study, A Randomized Clinical TrialSemantic proximity Read

Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac VaccinationSemantic proximity Read

Neutralizing Activities against the Omicron Variant after a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac VaccinationSemantic proximity Read

Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adultsSemantic proximity Read

Immunogenicity following two doses of BBIBP-CorV vaccine and a third booster dose with viral vector and Mrna COVID-19 vaccines against delta and omicron variants in prime immunized adults with two doses of BBIBP-CorV vaccineSemantic proximity Read

Safety and immunogenicity of a broad-spectrum mosaic vaccine as a booster dose against SARS-CoV-2 Omicron and other circulating variantsSemantic proximity Read

Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variantSemantic proximity Read

Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19Semantic proximity Read

Effectiveness of Homologous and Heterologous Covid-19 Boosters against OmicronSemantic proximity Read

COVID-19 mRNA Booster Vaccines Elicit Strong Protection Against SARS-CoV-2 Omicron Variant in Patients with CancerSemantic proximity Read

Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trialSemantic proximity Read

4th Dose COVID mRNA Vaccines’ Immunogenicity & Efficacy Against Omicron VOCSemantic proximity Read